Good
Partially Aligned
Patient Risk:
Medium
Summary
Most claims about colchicine prophylaxis for gout flares and common GI adverse reactions are supported by the provided label excerpts. However, several claims extend beyond the provided label text (e.g., acute-treatment use, general anti-inflammatory/heart-lining indications) or are stated more generally than the label (e.g., interaction safety wording, timing/strategy for acute attacks).
Category Scores
Accurate Statements
Colchicine tablets are used to prevent gout attacks.
Supported for prophylaxis of gout flares in adults (Section 1).
Colchicine reduces inflammation in response to gout flares triggered by urate crystals.
Mechanism postulated to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals (Section 12.1).
Colchicine is used to help prevent gout flares in people who have frequent attacks.
Label describes efficacy for gout flare prophylaxis; the provided excerpt indicates decreased frequency of gout flares with colchicine prophylaxis (Sections 1, 14).
Colchicine may be used after an acute gout attack to lower the chance of future flares.
Prophylaxis indication for gout flares (Section 1) is consistent with preventing future flares; the provided excerpt includes prophylaxis use generally (Sections 1, 14).
For prevention, colchicine is taken on a regular schedule to lower the frequency of future gout attacks.
Recommended prophylaxis dosage is 0.6 mg once or twice daily; administered orally without regard to meals (Section 2).
Common side effects of colchicine include diarrhea.
Diarrhea listed among common GI adverse reactions (Section 6).
Common side effects of colchicine include nausea.
Nausea listed among common GI adverse reactions (Section 6).
Common side effects of colchicine include vomiting.
Vomiting listed among common GI adverse reactions (Section 6).
Common side effects of colchicine include abdominal pain.
Abdominal pain listed among common GI adverse reactions (Section 6).
More serious colchicine toxicity is more likely with higher doses.
The label notes GI disorders as first signs of toxicity and fatal overdoses have been reported; dose-related toxicity context is supported (Sections 5.1, 6).
More serious colchicine toxicity is more likely with kidney impairment.
Severe renal impairment is associated with colchicine toxicity; dose reduction/alternatives should be considered (Section 8.6), and increased risk is noted for neuromuscular toxicity especially in impaired renal function (Section 5.4).
More serious colchicine toxicity is more likely with drug interactions.
Inhibition of CYP3A4 and/or P-gp may lead to colchicine-related toxicity; fatal drug interactions are reported (Sections 5.3, 7).
Colchicine may be unsafe if drug interactions or kidney or liver problems are present.
Label highlights toxicity risk with severe renal/hepatic impairment and with dual CYP3A4/P-gp inhibition (Sections 4, 5.3, 8.6, 8.7).
Unsupported Statements
Colchicine tablets are used to treat gout attacks.
The provided label excerpt for GLOPERBA indicates prophylaxis of gout flares; limitations state safety/effectiveness for acute treatment of gout flares during prophylaxis has not been studied (Section 1). No supported acute-treatment indication is shown in the provided excerpts.
For an acute gout attack, colchicine is taken early in the flare to reduce pain and swelling.
No acute treatment dosing/timing/pain-and-swelling claim is supported by the provided excerpts; Section 1 indicates limitations of use for acute treatment during prophylaxis and does not provide acute-treatment instructions.
Colchicine has anti-inflammatory uses in some clinical settings.
While mechanism relates to neutrophil-mediated inflammatory responses (Section 12.1), the provided excerpts do not support broad 'anti-inflammatory uses in some clinical settings' as an indication statement.
Colchicine is used in conditions involving inflammation of the lining around the heart, such as recurrent pericarditis.
No such indication is present in the provided label excerpts.
Colchicine should be used with clinician or pharmacist guidance in people taking other medications that increase the risk of side effects.
The excerpt specifically addresses interactions with inhibitors of CYP3A4/P-gp (and dual inhibitors) and contraindicated combinations in renal/hepatic impairment; it does not support a general statement about 'other medications' broadly increasing side effect risk.
Colchicine should be used with clinician or pharmacist guidance in people with kidney disease.
The label language provided indicates dose reduction/alternatives should be considered in severe renal impairment (Section 8.6) and contraindicates certain combinations in renal impairment (Section 4), but the broad wording 'should be used with guidance' is not an exact supported instruction.
Colchicine should be used with clinician or pharmacist guidance in people with liver disease.
Same issue: the excerpt provides specific precautions for severe hepatic impairment (Section 8.7) and contraindications for dual inhibitors in renal/hepatic impairment (Section 4), not a generalized 'guidance' statement.
Contradictions
Low
AI Statement
Colchicine tablets are used to treat gout attacks.
Label Reference
GLOPERBA indicated for prophylaxis of gout flares; limitations of use state safety/effectiveness for acute treatment of gout flares during prophylaxis has not been studied (Section 1).
Important Omissions
No mention that GLOPERBA is not an analgesic and should not be used to treat pain from other causes (Section 1).
Importance:
Moderate
No mention of specific prophylaxis maximum dose (maximum 1.2 mg/day) (Section 2).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims could mislead about acute gout treatment use and timing (not supported by provided excerpts) and interactions were generalized beyond the specific dual CYP3A4/P-gp inhibition and renal/hepatic impairment contraindication details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Claims about acute gout attack treatment and pericarditis are not supported by the provided label excerpts; interaction and population guidance are generalized rather than label-specific.
Suggested Improvement
Restrict indication statements to gout flare prophylaxis in adults; remove/avoid acute-treatment and recurrent pericarditis claims; align interaction language to dual CYP3A4 and P-gp inhibitors and the renal/hepatic impairment contraindications; include label limitations and dose maximum where applicable.